Bibliography
- Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow on protein products: a historical perspective. Nat Rev Drug Discov 2007;6:437-42
- Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
- Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011;71:1-10
- Karpusas M, Whitty A, Runkel L, et al. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 1998;54:1203-16
- Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-72
- Kling J. Fresh from the biologic pipeline—2010. Nat Biotechnol 2011;29:197-200
- Available from: http://www.statista.com/statistics/241962/top-producers-of-biopharmaceuticals-based-on-revenue-2011/ [Accessed on 7 June 2013]
- Available from: http://www.stellarix.com/blog/review-on-the-current-and-future-trends-of-biosimilar-market-in-usa-and-india/ [Accessed on 7 June 2013]
- Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars 2011;2011:1-11
- Marshall SA, Lazar GA, Chirino AJ, et al. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003;8:212-21
- Beck A. European medicines agency workshop on biosimilars monoclonal antibodies: perspective from the EU. MAbs 2009;1:406-10
- Schellekens H. Follow-on biologics: challenges of the ‘next generation’. Nephrol Dial Transplant 2005;20:iv31-6
- Available from: http://www.gabionline.net/Biosimilars/Research/Biosimilars-or-biobetters-what-does-the-future-hold/%28highlight%29/%20Biosimilars%20or%20biobetters%E2%80%93what%20does%20the%20future%20hold [Accessed on 7 June 2013]
- Dinwoodie N. Biobetters and the Future Biologics Market. BioPharm International 2011;24:31-5
- Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005;18:381-7